The Future of Vaccines

In the last few years, there have been key advancements in the field of vaccinations. Here, we discuss the current innovations in vaccine technology that are driving the future of healthcare.

vaccineImage Credit: Foxeel/

The rapid development of new vaccinations

Traditionally, vaccines take over a decade to research, develop, and be confirmed as safe for use in humans. For many years, scientists have recognized that this process is not fast enough to respond to novel infectious diseases.

Before COVID-19 emerged, scientists had been working on cutting-edge platform technologies to change the vaccine development landscape. In particular, a team at Imperial College London had been working on a groundbreaking new platform known as Rapidvac that aimed to develop new vaccines in months instead of years.

When COVID-19 became a global pandemic, scientists were under immense pressure to develop a new vaccine in a short timeframe. Thanks to developments like Rapidvac, scientists were equipped with the tools to create new vaccinations in record-breaking times. Before 2020, the fastest development of a vaccine had been the four years it had taken to get the mumps vaccine approved back in the 1960s.

What was achieved with the COVID-19 vaccines demonstrates a possible paradigm shift in vaccine development and deployment. It shows how vaccines can rapidly and effectively developed in short time frames to respond to novel diseases.

Syringe-less vaccines

Historically, syringes have been vital for administering vaccinations. Rates of trypophobia, the fear of needles, are fairly prevalent in the population, with recent studies estimating that around 20-50% of adolescents and 20-30% of young adults exhibit fear of needles. Therefore, the efficacy of controlling diseases via syringe-delivered vaccines is limited as there will always be a percentage of the population who will avoid taking the vaccine due to a phobia.

To overcome this issue, scientists are developing a method of delivering vaccinations via micro-patches. A team at the Hilleman Labs in India has recently developed such patches that could be used to vaccinate against Hepatitis B.

The method of patch-delivery also has further advantages, such as that they are cheap to make and easy to store, whereas many syringe-delivered vaccines are required to be kept at cold temperatures so that they remain viable. Therefore, patch-delivered vaccines offer rural and poor communities access to vaccinations that previously may have been out of their reach.

Micro-patches will make vaccines more accessible than ever | Wellcome

Iris scanning helps to establish digital vaccine records in developing countries

The 2014-2016 Ebola outbreak that hit West Africa was the largest and most complicated outbreak ever since the discovery of the virus back in the 1970s. Given that the average fatality rate of the disease is around 50%, providing those in at-risk areas with vaccination was vital to tackling the spread of the disease and preventing unnecessary deaths.

Fortunately, by 2014, two effective vaccines had been developed to protect against the Ebola virus. However, the challenge was that two doses of the vaccination were required, with the second dose administered 56 days after the first. In Western Africa, a developing area of the world, keeping track of who had received the vaccine and when they required the second dose was difficult given the lack of health infrastructure for tracking medical records.

To resolve this, scientists developed an innovative biometric tool to scan the iris and fingerprints of those receiving the vaccine. These scans were used to identify patients. Additionally, biometric tracking offered a way of tracking those who had been vaccinated in a non-stigmatizing manner, which was important in West Africa where many people did not want to be associated with Ebola.

The development of the biometric tracking method demonstrates a revolutionary way to manage vaccination deployment in developing countries that are often at greater risk of infectious viruses.

The future of vaccines: iris scanning technology is helping to contain outbreaks like Ebola

Infection research

A team of scientists in Kenya is currently developing a vaccine against the Shigella bacteria which is a major cause of infant death across the globe. The team is using an innovative protocol to investigate the efficacy of their vaccine.

Volunteers are being infected with the bacteria under test conditions in a controlled environment and being administered with the vaccine to quickly collect data on how effective the developing vaccine is against the bacteria. Studies like this could help speed up vaccine development for a number of diseases.

Advancements in vaccine technology, such as those discussed here will help shape the future of healthcare and will likely save many more lives from preventable diseases.


Further Reading

Last Updated: Jan 17, 2022

Sarah Moore

Written by

Sarah Moore

After studying Psychology and then Neuroscience, Sarah quickly found her enjoyment for researching and writing research papers; turning to a passion to connect ideas with people through writing.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Moore, Sarah. (2022, January 17). The Future of Vaccines. News-Medical. Retrieved on July 20, 2024 from

  • MLA

    Moore, Sarah. "The Future of Vaccines". News-Medical. 20 July 2024. <>.

  • Chicago

    Moore, Sarah. "The Future of Vaccines". News-Medical. (accessed July 20, 2024).

  • Harvard

    Moore, Sarah. 2022. The Future of Vaccines. News-Medical, viewed 20 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Groundbreaking mRNA vaccine administered to captive elephant to fight EEHV